{
    "clinical_study": {
        "@rank": "41686", 
        "arm_group": {
            "arm_group_label": "Flurpiridaz F18", 
            "arm_group_type": "Experimental", 
            "description": "Open-label study of a single injection of flurpiridaz F18 for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary cathertization"
        }, 
        "brief_summary": {
            "textblock": "The study will evaluate the use of Flurpiridaz F18 injection in patients with CAD to\n      determine if the study drug in PET imaging is better than SPECT imaging currently used for\n      this purpose."
        }, 
        "brief_title": "Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will assess the diagnostic efficacy (sensitivity and specificity) of Flurpiridaz\n      F18 Injection MPI in comparison with SPECT MPI in patients with known or suspected CAD. Six\n      hundred and seventy-two evaluable patients will be enrolled and will undergo SPECT MPI and\n      Flurpiridaz F18 PET MPI.  Patients will be considered for enrollment if they are scheduled\n      to undergo or have undergone prior ICA without intervention (being either positive or\n      negative for CAD)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Invasive Coronary Angiography Men or Women age 18 or older - see protocol for additional\n        details\n\n        Exclusion Criteria:\n\n        Women who are pregnant, lactating, or of child bearing potential who are not practicing\n        birth control Unstable cardiac status History of coronary artery bypass graft History of\n        PCI within the past six months See protocol for additional details"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681524", 
            "org_study_id": "BMS747158-302"
        }, 
        "intervention": {
            "arm_group_label": "Flurpiridaz F18", 
            "description": "Injection of Flurpiridaz F18 for the purposes of PET MPI analysis", 
            "intervention_name": "Flurpiridaz F18", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Flurpiridaz F18 Injection", 
            "Positron Emission Tomography Myocardial Perfusion Imaging", 
            "Single Positron Emission Computed Tomography", 
            "Coronary Artery Disease", 
            "Myocardia Ischemia", 
            "Coronary Disease", 
            "Heart Diseases", 
            "Cardiovascular Diseases", 
            "Arteriosclerosis", 
            "Arterial Occlusive Diseases", 
            "Vascular Diseases"
        ], 
        "lastchanged_date": "May 29, 2013", 
        "number_of_arms": "1", 
        "official_title": "A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)", 
        "overall_official": {
            "affiliation": "Lantheus Medical Imaging", 
            "last_name": "Cesare Orlandi, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Blinded Image assessment for PET & SPECT perfusion and for interventional coronary angiography", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Diagnostic performance evaluation of CAD (PETVsSPECT)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Diagnositic performance evaluation of multivessel disease (PETvsSPECT)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Detection of CAD in subgroups:  pharm stress, females and BMI>/=30", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Image quality of rest and stress (PETvsSPECT)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Diagnostic certainty evaluation of rest and stress (PETvsSPECT)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Evaluation of reversible defect size of rest and stress (PETvsSPECT)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Safety evaluation of flurpiridaz F 18 will include monitoring the number participants with adverse events (AEs), medication errors, treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs).", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Lantheus Medical Imaging", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lantheus Medical Imaging", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2013", 
        "why_stopped": "delayed study start"
    }
}